Glurenorm

Glurenorm is a prescription oral medication whose active ingredient is gliquidone, a sulfonylurea class antidiabetic agent. It is marketed in the European Union and is supplied as tablets of unspecified strength. Gliquidone works by stimulating insulin release from pancreatic beta cells, helping to lower blood glucose levels in adults with type 2 diabetes mellitus. The drug is intended for chronic management and is taken under medical supervision.

Glurenorm (gliquidone) is indicated for the oral treatment of type 2 diabetes mellitus in adults when diet, exercise, and other non‑pharmacologic measures are insufficient to achieve glycemic control.

- Improves fasting and post‑prandial blood glucose levels. - Can be used as monotherapy or in combination with other oral antidiabetic agents. - May be considered when patients require a sulfonylurea with a relatively short duration of action. - Supports long‑term glycemic management as part of a comprehensive diabetes care plan. - May be prescribed when renal function permits use of sulfonylureas.

The safety profile of Glurenorm reflects the typical effects observed with sulfonylurea medications.

Common: - Mild hypoglycemia, especially if meals are missed. - Nausea or abdominal discomfort. - Headache or dizziness. - Weight gain due to increased insulin activity.

Serious: - Severe hypoglycemia leading to loss of consciousness. - Allergic reactions such as skin rash, itching, or swelling. - Hepatic dysfunction indicated by elevated liver enzymes.

Before initiating Glurenorm, clinicians should evaluate several clinical factors to minimize risks and ensure appropriate use.

- Assess renal and hepatic function, as impairment may alter drug clearance. - Review history of hypoglycemia or sulfonylurea sensitivity. - Use caution in elderly patients due to increased susceptibility to low blood sugar. - Monitor blood glucose regularly during dose adjustments. - Advise patients to maintain consistent meal patterns to prevent hypoglycemia. - Consider pregnancy and lactation status; the safety profile is not well established. - Avoid use in patients with known allergy to sulfonylureas.

Glurenorm can interact with other medicines, affecting blood glucose levels or increasing the risk of adverse events.

Avoid: - Concurrent use with other sulfonylureas or insulin, which may cause profound hypoglycemia. - Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that can raise gliquidone concentrations. - MAO‑B inhibitors, which may potentiate hypoglycemic effects.

Use with caution: - Beta‑blockers, as they may mask hypoglycemia symptoms. - Thiazide diuretics, which can increase blood glucose. - Corticosteroids, which may reduce the drug’s glucose‑lowering efficacy.